Company

preclinics as a scientific organization and partner network

preclinics combines one contractual interface with specialized scientific sites across Europe. The company profile below consolidates the full content plan for launch-ready corporate communication.

Locations

Our sites across Europe

preclinics GmbH — Potsdam, Germany · Headquarter

The Potsdam headquarter covers bioanalytics, in vitro and in vivo studies in laboratory rodents and imaging technologies, together with administration and study planning. The BSL-2 laboratory supports work with GMOs. The in vivo unit performs PK, biodistribution and vaccination studies with µCT, bioluminescence and NIR-fluorescence imaging. For in vitro assays there is automated confocal microscopy for live cell imaging, flow cytometry and plate-based assays.

preclinics Italia s.r.l — Parma, Italy · Protein Development

preclinics Italia focuses on camelid antibody development, engineering and modification, including library technologies and screening approaches. Protein and antibody expression is performed in E. coli and yeast. Founded in 2022 out of a long-term collaboration with the University of Parma and located in the Tecnopolo building on the university campus.

Behring Campus Eystrup — Lower Saxony · Large Animal Facility

BCE runs immunization programs and preclinical studies in New World camelids, cattle, sheep, goats, poultry and rabbits, and produces antisera and other biological products. Veterinarians, laboratory technicians and animal caretakers work to defined scientific quality and animal welfare standards. The 3.6-hectare campus includes 24 buildings for animal husbandry, laboratories, offices and storage, with about 10 hectares of nearby pasture.

Timeline

Key milestones and achievements

2006

preclinics GmbH founded in Potsdam with a focus on preclinical CRO services.

2022

preclinics Italia launched as dedicated protein expression and camelid antibody hub.

2023-2025

Marseille Declaration commitment and strategic expansion of funded translational projects.

Funding and Cooperation

Current funded research programs

ProFIT (since 2018)

Platform for camelid antibody fragments (VHH) in diagnostics and therapy. Expanded from MRSA proof-of-concept to include SARS-CoV-2 therapeutic applications.

STARLITE (since 2024)

Engineering of sdAb libraries for novel tumor targets with integration into therapeutic virus constructs and licensing-oriented resource generation.

PHAROS (since 2024)

Point-of-care alternative to complex flow cytometry using camelid fragment behavior in cell-free systems for decentralized diagnostics.

BoNTANA (since 2025)

Nucleic acid-based Botulinum Neurotoxin A products for injectable and transdermal applications with extended efficacy and improved safety logic.

Join the team or collaborate on funded innovation programs

We are actively growing scientific, analytical, and operational roles and welcome strategic collaboration inquiries.

Contact Company Team Read resources